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The development of a biodegradable polymeric drug delivery system for the narcotic antagonist nal- 
trexone may improve patient compliance in the treatment of opiate addiction. Random copolymers 
consisting of the a-amino acids N 5- ( 3-hydroxypropyl)-L-glutamine and L-leucine were synthesized 
with equimolar initial monomer feeds. The molecular weight of this chemical carrier was determined 
by viscometry and wide-angle light scattering. In order to get selective covalent coupling of drug to 
polymer the 3-acetate derivative and the 14-acetate derivative of naltrexone were synthesized and 
characterized by NMR. Hydrolytic conversion of each monoacetate to parent drug was monitored by 
HPLC and the rate constant was determined. Both derivatives were coupled via hydrolytically labile 
carbonate linkages to the polymer hydroxyl groups. The drug conjugates were prepared as particles of 
various size ranges between 20 and 350 p. In vitro studies in phosphate-buffered saline (pH 7.4) dem- 
onstrated a release rate dependence on particle size. Nearly constant plasma levels of naltrexone were 
obtained for one month after subcutaneous injection in rats. 
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Introduction 
Opiate addiction presents a significant prob- 
lem to the health, safety and economic condition 
of many nations. For the treatment of opiate ad- 
dicts naltrexone hydrochloride is used due to its 
ability to antagonize opiates. Poor compliance is 
a major difftculty in patients receiving naltrex- 
one. Naltrexone does not directly relieve un- 
pleasant symptoms such as prolonged with- 
drawal or drug seeking behavior. Therefore, 
compliance becomes more tenuous [ 1,2]. 
The development of a long-term controlled re- 
lease system for the delivery of naltrexone has 
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been sought to overcome the problems associ- 
ated with compliance over several months or 
years of therapy. The National Institute on Drug 
Abuse has determined that a biodegradable po- 
lymeric delivery system that releases naltrexone 
at a constant rate is most desirable [31. 
The aim of our research is to develop an in- 
jectable system of polymeric prodrug particles 
which will release constant and effective levels of 
naltrexone in vivo for at least one month. In pre- 
vious studies we described the preparation and 
drug release characteristics of insoluble ma- 
cromolecular prodrugs of naltrexone bound to 
biodegradable polymers [ 4,5]. As carriers the 
polymer of N 5- ( 3-hydroxypropyl )-L-glutamine 
(HPG) and copolymers of HPG and leucine 
(Leu) were used. Naltrexone-3-acetate- 14
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hemisuccinate was bound across an ester bond 
with the hydroxyl groups of the polymeric car- 
rier. Conjugates were prepared both as discs and 
as particles. By increasing the content of hydro- 
phobic Leu residues in the polymeric carrier up 
to 50% the duration of in vitro naltrexone re- 
lease from particle-shaped conjugates could be 
increased to 15 days and acceptable plasma lev- 
els were obtained after subcutaneous injection in 
rats [ 5 1. To enhance the duration of naltrexone 
release from particle-shaped polymeric conju- 
gates we now have studied the use of a different 
type of drug-polymer bond [ 61. In this paper we 
report on particle-shaped naltrexone conjugates 
of P ( HPGSo/LeusO) in which the drug is bound 
at either the 3-position or the 14-position through 
a carbonate bond. The preparation and in vitro 
as well as in vivo drug release characteristics are 
described. 
Experimental 
Materials 
All materials were of reagent grade quality or 
better and used as received except as noted. 
Dioxane, tetrahydrofuran (THF), and absolute 
ethanol were stored over 4-81 molecular sieves 
before use. Triethylamine (TEA), dimethylfor- 
mamide (DMF), and acetic anhydride were dis- 
tilled prior to use. Triophosgene was obtained 
from Janssen (Belgium). Naltrexone hydrochlo- 
ride was obtained from the Research Triangle 
Institute and converted to the free base form 
(Nf ) before further modification [ 4 1. 
Methods 
Thin-layer chromatography (TLC) was per- 
formed using silica gel 6OF-254 precoated plastic 
or aluminum sheets (Merck) with chloroform/ 
methanol (4 : 1) as developer and visualized with 
UV light and Dragendorff’s reagent (Sigma 
Chemical Co.). High performance liquid chro- 
matography (HPLC) was performed by using a 
mobile phase of 60% methanol and 40% aqueous 
(0.25% TEA, 0.01% sodium octylsulfate, pH ad- 
justed to 6.7 with phosphoric acid) with apBon- 
dapak C- 18 (30 cm) column (Waters Associ- 
ates), and a Spheri-5 C- 18 guard column 
(Brownlee Labs) at a flow rate of I .O ml/min. 
Samples (usually 30 ~1) were injected, the UV 
absorbance at 254 nm detected, and peak heights 
recorded. Quantitation was done by comparison 
of peak heights to a standard curve. 
Viscometric measurements were made at 
25.0” ? 0.1 ‘C in dichloroacetic acid (DCA) with 
an Ubbelohde viscometer. Initial polymer con- 
centration was 0.2% (w/v) with two subsequent 
dilutions. Efflux time for solvent was 4 12 -t 1 s. 
Comparison of intrinsic viscosities with the lit- 
erature for HPG containing polymers yields the 
viscosity based molecular weight (Mv ) . 
Polymer samples for analysis by wide-angle 
light scattering (WALS) were prepared at var- 
ious concentrations indry DCA, usually 0.4,0.3, 
0.2, and 0.1% (w/v). Solutions were filtered 
through a 0.2 pm membrane to ensure complete 
removal of dust and fine particulates. The inten- 
sity of scattered light at angles ranging from 30” 
to 150” was determined using a FICA 50 WALS 
instrument with a mercury lamp (546 nm). Re- 
fractive indices of the copolymer/DCA solu- 
tions were measured at 25 “C with a Brice-Phoe- 
nix differential refractometer with a mercury 
lamp (546 nm). Construction of a Zimm plot al- 
lows for extrapolation of the inverse of the 
weight-averaged molecular weight (Mw ) . 
‘H and 13C NMR spectra were obtained using 
a JEOL HNM-FX 270 MHz Fourier transform 
NMR spectrometer. Naltrexone derivatives were 
dissolved in CDC13 and chemical shifts (8, ppm) 
were referenced to internal tetramethylsilane 
(TMS ). IR spectra were recorded using a Beck- 
man Microlab 620 MX computing spectrometer. 
Naltrexone and its derivatives were dissolved in 
acetone and allowed to dry on sodium chloride 
discs. Melting points were determined using a hot 
block Mel-Temp capillary melting point appara- 
tus and are uncorrected. 
Copoly(a-amino acid) carriers 
Random copolymers of HPG and Leu are ob- 
tained by a well known method involving the 
displacement of the y-benzyl group from copol- 
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ymers of y-benzyl+glutamate (BLG) and Leu 
by aminolysis [ 4-9 1. The copoly (BLG/Leu ) 
was synthesized utilizing equimolar quantities of 
the amino acid N-carboxyanhydride monomers 
in dioxane with TEA as catalyst (A/1=35) ac- 
cording to the general method of Blout et al. [ 10 ] 
as described in our previous study [ 41. Treat- 
ment of this copolymer with 3-aminopropanol for 
5 days produces the HPG/Leu copolymer with 
fewer than 3% residual benzyl groups remaining 
[ 7,8 1. Molecular weight was determined by both 
viscometry and wide-angle light scattering 
(WALS) analyses. 
Naltrexone monoacetate prodrugs 
Naltrexone-3-acetate (N3A) was synthesized 
according to a modification of a previously re- 
ported procedure [41. Nf (3.07 g) was reacted 
at O-5 ‘C with acetic anhydride ( 1.1 ml, 1.3 mol 
eq.) in THF (20 ml) with TEA (3.0 mol eq.) 
present as catalyst. After stirring overnight the 
solution was concentrated under high vacuum. 
The semi-solid product was purified by flash 
chromatography using 2% methanol in chloro- 
form as eluent and silica gel 60 as stationary 
phase. Subsequent crystallization from methyl- 
ene chloride/hexane gave N3A (3.21 g, 93.3%) 
after filtering and drying under vacuum; m.p. 
103-105°C; TLC, Rf0.84; HPLC, R, 11.9 min; 
‘H NMR 6, 6.86, 6.82, 6.69, 6.65 (H-l, H-2 AB 
quartet), 4.69 (H-5), 3.21 (H-9), and 2.31 (3- 
acetate methyl H); “C NMR 6,20.80 (3-acetate 
methyl C), 168.42 (3-acetate carbonyl C); IR, 
1730 cm-’ (6-keto), 1770 cm-’ (3-acetate). 
Naltrexone-14-acetate (N 14A) was synthe- 
sized by the selective deacylation of naltrexone- 
3,14-diacetate (N3,14A) [ 111. Nf ( 1.28 g) was 
refluxed in 25 ml freshly distilled acetic anhy- 
dride at 135 “C for 5 min and the temperature 
was decreased to 130°C. After 25 min the solu- 
tion was allowed to cool gradually to room tem- 
perature and was concentrated by rotary evapo- 
ration. The pH of the residue was adjusted to a 
value of about 8 with prechilled 5% sodium bi- 
carbonate. Extraction into methylene chloride 
(50 ml) twice, evaporation, and crystallization 
from toluene/hexane yielded 1.26 g of N3,14A 
(78.7%); m.p. 144.5-146°C (see lit. in [ 111 
146-147”(Z); TLC, Rf0.93; HPLC, R, 14.7 min; 
‘H NMR S, 6.87, 6.83, 6.70, 6.66 (H-l, H-2 AB 
quartet), 4.69 (H-5), 4.47 (H-9), and 2.31 (3- 
acetate methyl H), 2.19 ( 14-acetate methyl H); 
r3C NMR 6,20.73 (3-acetate methyl C), 168.27 
(3-acetate carbonyl C), 22.14 ( 14-acetate methyl 
C), 170.03 (1Cacetate carbonyl C); IR, 1735 
cm-’ (6-keto, lCacetate), 1765 cm-’ (3- 
acetate ) .
Selective deacetylation of N3,14A ( 1.25 g) in 
4% sulfuric acid (40 ml) overnight at room tem- 
perature was followed by basification and ex- 
traction with methylene chloride. The organic 
layer was dried over anhydrous odium sulfate 
for 12 h at 4” C, filtered, and methylene chloride 
was evaporated under vacuum, giving a white 
residue. The crude product was crystallized from 
methylene chloride/hexane to give 0.75 g of 
N14A (66.0%); m.p. 192-194°C; TLC, R,0.87; 
HPLC,R,10.8min;‘HNMRS,6.75,6.71,6.62, 
6.58 (H-l, H-2 AB quartet), 4.68 (H-5), 4.48 
(H-9), and 2.21 ( 1Cacetate methyl H); 13C 
NMR 6, 22.86 ( 1Cacetate methyl C), 170.11 
(1Cacetate carbonyl C); IR, 1725 cm-’ (6-keto, 
14-acetate). 
In vitro hydrolysis of naltrexone prodrugs 
To demonstrate the facile conversion of the 
prodrug intermediates to naltrexone, in vitro hy- 
drolysis studies were performed. The hydrolytic 
medium was phosphate-buffered saline (PBS, pH 
7.4,37”C). Typically, a prodrug sample ( 10 mg) 
was dissolved in 200 ~1 of ethanol and then added 
to PBS (25.0 ml). Aliquots (50 ~1) were taken 
for various time intervals and quenched by rapid 
cooling with liquid nitrogen. Quantitation of 
naltrexone and the esters was accomplished by 
HPLC. 
Copoly(ar-amino acid)-naltrexone conjugates 
A solution of 0.50 g N14A in 10 ml of chloro- 
form was added drop-wise to 1 .O g of triphosgene 
in chloroform (20 ml) and TEA (0.7 ml) with 
stirring and was allowed to react for 1 h before 
an additional 1.4 ml of TEA were added. After 4 
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h (N 14A) or 22 h (N3A) reaction time the drug 
solution was evaporated to near dryness under a 
stream of dry nitrogen and a solution of 0.50 g of 
P ( HPG’“/Leu50) in 27 ml of chloroform/DMF 
(5 : 4) was added at once, and the mixture was 
stirred for 40 h. Solid polymer-drug conjugate 
was isolated by drop-wise addition of the reac- 
tion solution to 1800 ml of ether, washed with 
200 ml ether, redissolved in 50 ml of absolute 
ethanol, and reprecipitated in 1400 ml of ether. 
The product was filtered and dried in vacua to 
constant weight (0.62 g ). 
Both batches were ground into particles with a 
model CBM-1 (Black and Decker, Shelton, 
U.S.A.) electronic mill grinder. The powders 
were passed through sieves of predetermined 
mesh sizes to get various particle size ranges (20- 
50, 50-100, 100-200, and 200-350 pm) to in- 
vestigate particle size effects on drug release. 
To determine the extent of drug loading poly- 
mer-drug conjugate samples of known weight 
were dissolved in 2% methanolic KOH and 
stirred overnight at room temperature. The 
amount of drug in solution was quantified by 
HPLC analysis and comparison to a standard 
curve. No degradation of naltrexone was seen in 
a control consisting of drug dissolved in the same 
solvent. 
In vitro release studies 
Polymeric prodrug samples of known weight 
and particle size were placed in dialysis bags 
(molecular weight cut-off= 3500). The bags were 
filled with 250 @ of phosphate-buffer saline 
(PBS, pH 7.4,O. 1% NaNj) and tied such that a 
minimum of air remained inside. These bags 
were then immersed in 5.0 ml of PBS within a 
silanized test tube with screw-top lids. The tubes 
were then placed in a shaker water bath 
(37.0 +- 0.3”C, 50 strokes/min, 2.0 cm/stroke). 
Samples were collected daily and the entire re- 
lease medium was replaced with fresh PBS. Sam- 
ples were stored at 4°C until naltrexone was 
quantified by HPLC analysis. Systems were 
studied in triplicate. 
In vivo release studies 
Female Sprague-Dawley rats ( 180-200 g) 
were chosen as the animal model because of their 
ease of handling and the precedent set in pre- 
vious narcotic antagonist studies regarding the 
use of rats [ 12,13 1. Rats were housed for the du- 
ration of the studies and were allowed to con- 
sume food and water ad libitum with 12-h pe- 
riods of light and dark daily. At the conclusion of 
the experiments the rats were killed by carbon 
dioxide asphyxiation. Naltrexone concentration 
in rat plasma was determined by gas chromato- 
graphy coupled with negative ion chemical ioni- 
zation mass spectrometry [ 141. 
Preweighed amounts of polymeric prodrug 
conjugate (between 10 and 32 mg) were placed 
in l.O-ml syringes with 18-gauge needles. Rats 
were lightly anesthetized with ether and the hair 
around the site of injection shaved. Injection of 
the particles (50-l 00 pm) as a suspension in 
sterile saline ( (0.3 ml total volume) was made 
into the dorsal side of the rat’s neck. Any conju- 
gate remaining in the needles and syringes was 
recovered, dried, and weighed. All studies were 
performed in triplicate, although periodically in- 
dividual rats resisted sampling and thus were 
skipped. 
The conjugates had all been washed with 
ethanol during their final preparations and were 
assumed to be sterile. However, to minimize any 
chance of infection tetracycline was included in 
the drinking water for the first week of the study. 
Blood was drawn by carefully snipping the very 
end ( < 1 mm) of the rat’s tail which was then 
‘milked’ for collection. Without the milking pro- 
cess, the blood flow stopped almost immedi- 
ately. Samples (usually 50-500 pl) were col- 
lected in Becton Dickinson Microtainer brand 
capillary whole blood collectors with EDTA as 
anticoagulant. Plasma was separated by centrif- 
ugation, stored in silanized tubes, and frozen at 
- 20 o C until analyzed by GC/MS. Plasma con- 
centrations are expressed as ng/ml/mg 
conjugate. 
Results and discussion 
Design characteristics ofnaltrexone delivery 
systems 
The ideal naltrexone delivery system would 
have the following characteristics: (i) adminis- 
tration by injection, (ii) no adverse tissue reac- 
tion, (iii) relatively constant drug release, and 
(iv ) biodegradability. The biodegradable poly- 
meric naltrexone delivery systems tudied to date 
include many approaches using different copol- 
ymers, geometries, and drug loading amounts (4- 
6,15-l 7). Injection of particles is preferred to 
surgical implantation of larger devices such as 
films, discs, or rods. Large devices can be easier 
to remove from a patient if complications arise, 
but particles may also be recovered in surgery by 
scraping the subcutaneous area after administra- 
tion of a local anesthetic. Particles were also 
shown to be less inflammatory than films [ 18 1. 
Polymeric prodrug systems are composed of an 
active agent covalently bound to a polymeric 
backbone through a labile bond. These systems 
can be soluble for site-specific delivery or insol- 
uble for systemic delivery of active agents. Five 
major design considerations are important in 
tailoring a polymeric prodrug system to give the 
desired release characteristics: (i ) hydrophilic 
character and molecular weight of the polymer, 
(ii) type and length of spacer between drug and 
polymer, (iii) lability of the covalent linkage, 
(iv) initial drug loading, and (v) particle size or 
geometry of the device. The drug release rate 
from the designed system is controlled by one or 
more of the following processes: water permea- 
tion, hydrolysis of the labile drug-polymer bond, 
drug diffusion or degradation of the matrix. In 
general, the rate of hydrolysis will be slower than 
the rates of water permeation and drug diffusion 
and the release rate is expected to be governed 
by the rate of hydrolysis. Insoluble polymeric 
prodrugs of contraceptive steroids have exhib- 
ited long-term constant release both in vitro and 
in vivo [ 15,171. 
Preparation of biodegradable copolymer of N5(3- 
hydroxypropyl)-L-glutamine a dleucine as drug 
carrier 
Biodegradable devices possess all of the ad- 
vantages of nondegradable systems uch as long- 
term delivery capability, controlled delivery and 
increased patient compliance [ 191. A unique 
advantage of biodegradable devices is elimina- 
tion of the need for surgical removal of the de- 
vice after depletion of the drug. 
Poly (amino acids ) represent aclass of biode- 
gradable polymers with a wide variety of physi- 
cal and chemical properties which can be manip- 
ulated to tailor a specific system. Due to the wide 
range of amino acids commercially available, 
many different polymers and copolymers can be 
synthesized. Synthetic poly (a-amino acids) are 
known to be biodegradable [ 201. Those poly ( CX- 
amino acids) that have shown the greatest po- 
tential utility in designing drug delivery systems 
are homopolymers of L-glutamic acid or L-aspar- 
tic acid and copolymers of these amino acids with 
L-leucine and r_-valine [2 11. The polymers of 
these amino acids contain free carboxyl groups 
on the pendant side chains. These side chains 
may be modified by esterification or amidation 
to make a nonionizable and more hydrophobic 
derivative [7,8 1. Particularly useful has been the 
development of poly (hydroxyalkyl-L-gluta- 
mines) in which the side chain has been ex- 
tended and rendered nonionizable while retain- 
ing a hydrophilic group [ 8 1. The pendant side 
chains have been modified by covalent coupling 
of bioactive agents through hydrolytically labile 
linkages to give polymeric prodrugs [4-6, 
15-171. 
In our previous studies copolymers of HPG 
and Leu with varying amounts of Leu were used 
as the carrier in disc- and particle-shaped nal- 
trexone conjugates [ 4,5 1. By increasing the con- 
tent of Leu residues from 10 to 50% the in vitro 
drug release rate from particles was observed to 
decrease, which is probably due to the decreased 
water permeability of the polymer-drug conju- 
gate [ 5 1. However, even with 50% incorpora- 
tion of Leu residues the device was exhausted 
after 15 days [ 51. To enhance the duration of 
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drug release the SO/SO HPG/Leu copolymer was 
chosen for the preparation of conjugates with a 
hydrolytically more stable drug-polymer bond 
[ 6 1. This copolymer has been shown to undergo 
degradation in vitro [ 201. 
A random copolymer of y-benzyl-L-glutamate 
(BLG) and Leu was prepared by polymerisation 
of an equimolar mixture of the amino acid N- 
carboxyanhydride monomers in dioxane using 
TEA as the catalyst according to the method of 
Blout et al. [ lo]. Treatment of the copolymer 
with 3-aminopropanol for 5 days yields the 
HPG/Leu copolymer. The molecular weight of 
each polymer was determined by viscometry and 
WALS (Table 1) . From WALS absolute molec- 
ular weight values (Mw ) of 134 000 (BLG/Leu 
copolymer) and 76 100 (HPG/Leu copolymer) 
were obtained. The viscosity values agree rea- 
sonably well with the WALS results although the 
incorporation of Leu into the polymers does not 
allow exact viscometric omparisons with the lit- 
erature data obtained for the homopolymers 
PBLG and PHPG [ 8,221. 
Preparation and in vitro hydrolysis of naltrexone 
monoacetate prodrugs 
Naltrexone has two groups for possible bond 
formation, the 3-phenolic and 14-tertiary hy- 
droxyls (see Fig. 1). In order to facilitate selec- 
tive coupling of the drug with the polymeric car- 
rier the 3-acetate (N3A) and 1Cacetate (N14A) 
derivatives of naltrexone were synthesized. N3A 
was prepared as described previously [ 4 1. N 14A 
was prepared by selective hydrolysis of naltrex- 
one-3,14-diacetate (N3,14A) [ 111 with diluted 
sulfuric acid as described for naloxone-3,14-di- 
TABLE I 
Copoly(a-amino acid) molecular weights 
Copolymer (tlrplc)o.z~ [tll Wdc Mv Mw 
(Wg) (cd/g) (X IV) (X 10-3) 
P(BLG=‘/L~u’~) 0.96 0.91 0.058 145” 134 
P(HPGSo/Leuso) 0.62 0.72 0.084 60.3b 76.1 
* Estimated from [q] vs. molecular weight plot of Mitchell et al. [ 221. 
b Estimated from [q] vs. molecular weight plot of Lupu-Lotan et al. 
1'31. 
acetate [23 1. The compounds were found to be 
homogenous as judged from the sharp melting 
point and from TLC and HPLC. The chemical 
structure of each monoacetate was confirmed by 
‘H and 13C NMR spectroscopy [ 4,6]. 
The conversion of both monoacetate prodrugs 
back to naltrexone was accomplished by hydrol- 
ysis in phosphate-buffered saline at pH 7.4. To 
show that generation of parent drug will occur if 
an ester derivative is released from the polymer- 
drug conjugate the rates of ester hydrolysis were 
assessed. The first-order ate constant for the hy- 
drolysis of the phenolic acetate ster to parent 
drug ( k3-mc = 6.84~10~~ min-‘) is approxi- 
mately an order of magnitude less than that seen 
for the tertiary ester ( klcoa,= 7.62 x 10V3 
min-’ ) under the conditions employed. The 
surprisingly fast hydrolysis of the 1Cester may 
be explained by intramolecular catalysis by the 
nitrogen lone pair and the electron withdrawing 
nature of the nitrogen (especially when proton- 
ated, pK, = 8.13) resulting in an electron-defi- 
cient carbonyl carbon. 
The relatively slow conversion of the 3-acetate 
may not present a problem with regards to bioac- 
tivity, as it has been shown that naloxone-3-ace- 
tate has 60% greater activity in dogs than the 
parent drug [ 231. Naloxone is a narcotic antag- 
onist structurally similar to naltrexone having an 
N-ally1 group rather than an N-cyclopropylme- 
thy1 group at the 17 position. Similarly, the re- 
lease of naltrexone 1Cacetate is acceptable in 
view of the enhanced bioactivity of naloxone- 14- 
acetate compared with naloxone. Interestingly, 
the diacetate of naloxone actually demonstrated 
decreased activity versus the parent drug [ 23 1. 
The half-life of the 1Cacetate ster in PBS is 
about 90 min, while that of the phenolic acetate 
is 1000 min. It is likely that ester hydrolysis rates 
in vivo would be faster due to the presence of 
non-specific esterases in plasma. Salicylate es- 
ters of the naltrexone phenolic hydroxyl moiety 
were shown to have plasma half lives of about 30 
min in dogs and humans [ 241. 
Preparation of polymeric naltrexone conjugates 
In previous studies naltrexone release from 
polymeric conjugates required the hydrolysis of 
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ester bonds between drug and carrier [ 4,5 3. In 
view of the relatively fast hydrolyses of the 
monoa~tate prodrugs of naltrexone we antici- 
pated that linkage of the drug with the polymer 
across a hydrolytically more stable carbonate 
bond may result in a slower ate and a prolonged 
duration of drug release. 
The synthetic scheme for coupling of naltrex- 
one monoacetates to hydroxyl~nt~ning poly- 
mers using a carbonate bond is outlined in Fig. 
1. 
Naltrexone-3 acetate (N3A) and naltrexone- 
1Cacetate (N14A) were reacted with triphos- 
gene in the presence of t~ethyl~ine (TEA). 
TEA was chosen as the base catalyst due to its 
demonstrated superiority over other bases (pyr- 
idine, lutidine, 4-dimethyl-aminopyridine and 
dimethylformamide) in model reactions. The 
resultant chloroformate of each monoacetate was 
I T~ph~gene, TEA 
I 
Polymer 
reacted with P ( HPGso/LeuSo) in situ to give a 
carbonate-bound drug-polymer conjugate. 
The carbonate bound conjugates were loaded 
with 11.3% (w/w) (N3A) and 8.4% (w/w) 
(N 14A), respectively. The low drug loading of 
the conjugates i  tentatively explained by the ex- 
treme sensitivity of the chloroformate interme- 
diates to traces of water in the reaction mixture. 
In vitro release characteristics of polymeric 
naltrexone conjugates 
The polymeric prodrugs can be fashioned into 
various device forms affecting the rate of drug 
release. Particulate devices will generally release 
drug in a non-constant declining rate in vitro. 
However, the boundary layers that can exist in 
vivo may provide for constant drug release. Ear- 
lier work utilized discs and particles of various 
Triptrosgene, 
TEA 
I 
Polymer 
Fig. 1. Coupling of naltrexone monoacetates to P(HPGSo/LdO). 
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HPG/Leu copolymers coupled to naltrexone via 
ester linkages [ 4-6 1. The carbonate-bound con- 
jugates of N3A or N 14A and P ( HPG50/Leu50) 
were ground and passed through sieves yielding 
particles of various size ranges to study the influ- 
ence of total surface area on drug release. 
Figure 2 shows the cumulative naltrexone re- 
lease with time from the N 14A-bound conjugate 
in which coupling was effected through the phe- 
nolic 3-OH. A relatively large burst is observed 
for all particle sizes up to a cumulative fraction 
of released rug equal to 0.2-0.4 dependent on 
the size range. After the burst the release rate be- 
comes almost constant for each size range. 
Smaller particles release drug more quickly than 
larger particles both during the burst phase and 
afterwards. Release rates after the initial burst 
averaged 49.7, 33.9, 30.1, and 24.5 ,ug/day/ 100 
mg conjugate for the particles sized 20-50, 50- 
100, 100-200, and 200-350 pm, respectively. 
Particles of the conjugate of N3A having a car- 
bonate bond between the tertiary 14-OH and the 
polymer also displayed a slight burst followed by 
near constant release of naltrexone. The cumu- 
lative fraction drug release from these various 
sized systems is plotted versus time in Fig. 3. 
Particle size effects similar to the N14A car- 
bonate bound conjugate were observed. The nal- 
trexone release rates following the burst period 
averaged 110.9, 102.5, 87.4, and 79.0 pg/day/ 
100 mg conjugate for the particle size series 20- 
50, 50-100, 100-200, and 200-350 ,um. These 
time (days) 
Fig. 2. Cumulative fraction naltrexone released from N 14A- 
copoly( HPG50/Leu50) conjugate particles of various sizes. 
: 
8 
1 
10 20 30 
time (days) 
Fig. 3. Cumulative fraction naltrexone released from N3A- 
copoly (HPGSo/L.euSo) conjugate particles of various sizes. 
rates are at least wo times greater than those seen 
for the N 14A conjugate, which may be explained 
by an enhanced hydrolytic lability of the carbon- 
ate bond at position 14 of the drug similar to that 
observed for the monoacetates. 
The carbonate-bound naltrexone conjugates 
were obtained with much lower drug loadings 
than previously studied ester-bound conjugates 
preventing a direct comparison of the effect of 
linkage type. The much lower rates of naltrexone 
release observed for the carbonate-bound conju- 
gates may be due to lower drug loading, bond 
type, or a combination of both factors. 
The burst effect observed for both conjugates 
in the initial stages of release may be due to phys- 
ically adsorbed rug, an excess of drug moieties 
oriented outwards at the surface, edge effects, 
hydrophilic impurities acting as swelling enhan- 
cers, or copolymer chains with higher HPG con- 
tent which solvate faster and release the drug 
more quickly. 
In vivo release characteristics of polymeric 
naltrexone conjugates 
The carbonate-bound polymeric prodrugs of 
naltrexone were tested in vivo by examination of 
their plasma naltrexone profiles after subcuta- 
neous injection of the conjugate particles in rats. 
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Plasma was analyzed by GC/MS and the con- 
centrations were normalized to volume of sam- 
ple obtained and amount of conjugate injected. 
The analytical method only provided for quan- 
titation of free naltrexone xcluding analysis of 
the acetate prodrugs. 
The conjugates of naltrexone monoacetates 
demonstrated burst effects in vivo (Figs. 4 and 
5). 
Plasma levels in the early stage of delivery were 
between 2 and 4 ng/ml/mg conjugate for both 
the N3A and N14A devices. After the burst 
plasma naltrexone levels averaged 1.03 2 0.52 
h 51 I 
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Fig. 4. Plasma naltrexone levels following injection of Nl4A- 
cop~ly(HPG~~/L.eu~~) conjugate particles (50-100 pm) 
subcutaneously in rats ( n = 3 ) . 
10 
Time (days) 
20 30 
Fig. 5. Plasma naltrexone levels following injection of N3A- 
cop~ly(HPG~~/Leu~~) conjugate particles (So-100 pm) 
subcutaneously in rats (n = 3). 
ng/ml/mg conjugate injected for the N14A po- 
lymeric prodrug and 0.70 2 0.39 ng/ml/mg con- 
jugate injected for the N3A conjugate. 
Bursts may be caused by physically adsorbed 
drug and surface effects, but are also likely to be 
due to the conditions present within the subcu- 
taneous ite. An initial period of inflammation is 
common, and this is accompanied by a decrease 
in local pH. Rapid infiltration of the implant site 
by macrophages can provide for an increased 
level of enzyme activity which can also contrib- 
ute to any burst. Similarly, the periods of more 
constant release may be influenced by the for- 
mation of a fibrous capsule around the particles. 
Assuming that the volume of distribution of 
naltrexone per kilogram of body weight is of the 
same order of magnitude for both rats and hu- 
mans, similar plasma levels in humans could 
possibly be realized with subcutaneous injec- 
tions of 100-500 mg. 
Conclusions 
In the present study the preparation as well as 
in vitro and in vivo drug release characteristics 
of naltrexone conjugates of a biodegradable co- 
polymer of N 5- ( 3-hydroxypropyl )-L-glutamine 
and L-leucine was investigated. By linking nal- 
trexone monoacetates at either the 3- or 14-po- 
sition through a carbonate bond with the poly- 
meric carrier the in vitro drug release rate from 
particles was favourably suppressed compared 
with ester-bound conjugates tudied previously 
[ 4,5 1. The in vivo release of drug in rats showed 
therapeutically promising values of the mean 
plasma level for at least one month. The conju- 
gate design may be improved by achieving higher 
drug loads and by diminishing the in vitro and 
in vivo burst effects. The results warrant a more 
detailed study of the in vitro and in vivo mech- 
anism of drug release from the polymeric 
conjugates. 
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